Medpace: A Compelling Long-Term Opportunity Amid Short-Term Headwinds (Rating Upgrade)

Medpace (NASDAQ: MEDP ) is a rapidly-growing clinical research organization, providing full-service Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The current CEO, August Troendle, founded the company after gaining extensive experience of the difficulties faced by emerging biotech companies in a 22-year-old self-taught investor, who is currently aiming for his Master of Science in Business Administration with focus on finance and accounting, mean ...